

Reference: FOI.ICB-2526/039

Subject: Managing Pancreatic Cancer Enzyme Replacement Therapy (PERT)

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
<p>1. Has your ICB developed any local planning documents, protocols or guidance specifically relating to managing pancreatic cancer enzyme replacement therapy (PERT) shortages, including but not limited to Creon, between January 2023 and present? Please respond with yes or no.</p> <p>a. If yes to question 1, please provide copies of all such documents, protocols or guidance.</p>	<p>Yes. The ICB has a management of stock shortages page for system colleagues which does include details of and relevant guidance in relation to PERT. This page is for health care professionals and is not a patient facing webpage. This includes national guidance, BNSSG local pathway as well as information regarding the National Patient Safety Alert.</p> <p>Management of Stock Shortages (Remedy BNSSG ICB)</p> <p>The local pathways covers all indications for PERT not specifically for cancer as raised in FOI.</p>
<p>2. Has your ICB procured any alternative PERT products from overseas suppliers between January 2023 and present? Please respond with yes or no.</p> <p>a. If yes to question 2, please answer the following:</p> <p>i. Which countries were these products sourced from?</p> <p>ii. How many 'special order' prescriptions for these products have been dispensed?</p> <p>iii. What percentage of the local demand has been covered by these overseas products?</p>	<p>No</p>

<p>iv. How many Trusts within your ICS have used these products?</p>	
<p>3. Please provide details of:</p> <ul style="list-style-type: none"> a. Any risk assessments conducted regarding PERT / Creon shortages and; b. Any monitoring systems put in place to track local supply levels, between January 2023 and present. 	<ul style="list-style-type: none"> a. To determine risk we reviewed patient numbers to determine how many patients could be affected and brought system colleagues together with specialist knowledge to review stock volumes in the system (provider procurement teams monitoring stock), review Specialist Pharmacy Services website for stock updates, determine risks to patients and mitigations and also devised the pathway to supply patients going forward. "Pathway for patients who cannot obtain PERT supplies using their usual nominated pharmacy", here: Management of Stock Shortages (Remedy BNSSG ICB). b. As above meetings continue with the hospital Trust to monitor any PERT supply concerns via the local pathway. Stock shortages are detailed in the ICB risk register.

The information provided in this response is accurate as of 13 May 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.